C16 or ISRIB treatment restores PP1, dephosphorylates eIF2α, terminates maladaptive ISR signals in the pulmonary vascular endothelium, and mitigates PVOD phenotypes in rats. This evidence concerns the gene EIF2A and pulmonary venoocclusive disease.